#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Recognizing patients with monogenic
3-1	15-26	Recognizing	_	_	_	_
3-2	27-35	patients	person[3]	new[3]	ana	4-5[0_3]
3-3	36-40	with	person[3]	new[3]	_	_
3-4	41-50	monogenic	person[3]|abstract	new[3]|new	_	_

#Text=AIDs is difficult because their clinical spectrum may range from very mild inflammatory episodes to severe chronic disease .
4-1	51-55	AIDs	abstract	new	coref	11-6
4-2	56-58	is	_	_	_	_
4-3	59-68	difficult	_	_	_	_
4-4	69-76	because	_	_	_	_
4-5	77-82	their	person|abstract[7]	giv|new[7]	coref|coref	6-19|6-19
4-6	83-91	clinical	abstract[7]	new[7]	_	_
4-7	92-100	spectrum	abstract[7]	new[7]	_	_
4-8	101-104	may	_	_	_	_
4-9	105-110	range	_	_	_	_
4-10	111-115	from	_	_	_	_
4-11	116-120	very	abstract[8]	new[8]	_	_
4-12	121-125	mild	abstract[8]	new[8]	_	_
4-13	126-138	inflammatory	abstract[8]	new[8]	_	_
4-14	139-147	episodes	abstract[8]	new[8]	_	_
4-15	148-150	to	abstract[8]	new[8]	_	_
4-16	151-157	severe	abstract[8]|abstract[9]	new[8]|new[9]	coref	5-3[10_9]
4-17	158-165	chronic	abstract[8]|abstract[9]	new[8]|new[9]	_	_
4-18	166-173	disease	abstract[8]|abstract[9]	new[8]|new[9]	_	_
4-19	174-175	.	_	_	_	_

#Text=Moreover , the disease features significantly overlap .
5-1	176-184	Moreover	_	_	_	_
5-2	185-186	,	_	_	_	_
5-3	187-190	the	abstract[10]	giv[10]	_	_
5-4	191-198	disease	abstract[10]	giv[10]	_	_
5-5	199-207	features	_	_	_	_
5-6	208-221	significantly	_	_	_	_
5-7	222-229	overlap	_	_	_	_
5-8	230-231	.	_	_	_	_

#Text=Our targeted NGS approach resulted in genetic confirmation in a relatively small proportion ( 7 % ) of patients .
6-1	232-235	Our	person|abstract[13]	acc|new[13]	ana|coref|ana|coref	7-29|20-4[123_13]|7-29|20-4[123_13]
6-2	236-244	targeted	abstract[13]	new[13]	_	_
6-3	245-248	NGS	place|abstract[13]	new|new[13]	coref	13-10[81_0]
6-4	249-257	approach	abstract[13]	new[13]	_	_
6-5	258-266	resulted	abstract	new	none|none	6-5[0_180]|25-9
6-6	267-269	in	_	_	_	_
6-7	270-277	genetic	abstract[14]	new[14]	coref	19-15[111_14]
6-8	278-290	confirmation	abstract[14]	new[14]	_	_
6-9	291-293	in	abstract[14]	new[14]	_	_
6-10	294-295	a	abstract[14]|quantity[15]	new[14]|new[15]	appos	6-15[16_15]
6-11	296-306	relatively	abstract[14]|quantity[15]	new[14]|new[15]	_	_
6-12	307-312	small	abstract[14]|quantity[15]	new[14]|new[15]	_	_
6-13	313-323	proportion	abstract[14]|quantity[15]	new[14]|new[15]	_	_
6-14	324-325	(	_	_	_	_
6-15	326-327	7	quantity[16]	giv[16]	coref	24-8[155_16]
6-16	328-329	%	quantity[16]	giv[16]	_	_
6-17	330-331	)	_	_	_	_
6-18	332-334	of	_	_	_	_
6-19	335-343	patients	person	giv	coref	11-20[64_0]
6-20	344-345	.	_	_	_	_

#Text=This finding is consistent with two 2019 reports by Karacan et al. and Papa et al. , who used recent guidelines for the definition of positive diagnosis as we did .
7-1	346-350	This	abstract[18]	new[18]	_	_
7-2	351-358	finding	abstract[18]	new[18]	_	_
7-3	359-361	is	_	_	_	_
7-4	362-372	consistent	_	_	_	_
7-5	373-377	with	_	_	_	_
7-6	378-381	two	abstract[19]	new[19]	coref	9-2[32_19]
7-7	382-386	2019	abstract[19]	new[19]	_	_
7-8	387-394	reports	abstract[19]	new[19]	_	_
7-9	395-397	by	abstract[19]	new[19]	_	_
7-10	398-405	Karacan	abstract[19]|person	new[19]|new	_	_
7-11	406-408	et	abstract[19]	new[19]	_	_
7-12	409-412	al.	abstract[19]	new[19]	_	_
7-13	413-416	and	abstract[19]	new[19]	_	_
7-14	417-421	Papa	abstract[19]|person	new[19]|new	_	_
7-15	422-424	et	abstract[19]	new[19]	_	_
7-16	425-428	al.	abstract[19]	new[19]	_	_
7-17	429-430	,	_	_	_	_
7-18	431-434	who	_	_	_	_
7-19	435-439	used	_	_	_	_
7-20	440-446	recent	abstract[22]	new[22]	_	_
7-21	447-457	guidelines	abstract[22]	new[22]	_	_
7-22	458-461	for	abstract[22]	new[22]	_	_
7-23	462-465	the	abstract[22]|abstract[23]	new[22]|new[23]	coref	8-5[27_23]
7-24	466-476	definition	abstract[22]|abstract[23]	new[22]|new[23]	_	_
7-25	477-479	of	abstract[22]|abstract[23]	new[22]|new[23]	_	_
7-26	480-488	positive	abstract[22]|abstract[23]|abstract[24]	new[22]|new[23]|new[24]	coref	9-49[46_24]
7-27	489-498	diagnosis	abstract[22]|abstract[23]|abstract[24]	new[22]|new[23]|new[24]	_	_
7-28	499-501	as	_	_	_	_
7-29	502-504	we	person	giv	ana	10-3
7-30	505-508	did	_	_	_	_
7-31	509-510	.	_	_	_	_

#Text=Three previous studies using a broader definition claimed 19 % , 20 % , and 22 % diagnostic yield .
8-1	511-516	Three	event[26]	new[26]	_	_
8-2	517-525	previous	event[26]	new[26]	_	_
8-3	526-533	studies	event[26]	new[26]	_	_
8-4	534-539	using	_	_	_	_
8-5	540-541	a	abstract[27]	giv[27]	coref	10-3[48_27]
8-6	542-549	broader	abstract[27]	giv[27]	_	_
8-7	550-560	definition	abstract[27]	giv[27]	_	_
8-8	561-568	claimed	_	_	_	_
8-9	569-571	19	quantity[28]	new[28]	_	_
8-10	572-573	%	quantity[28]	new[28]	_	_
8-11	574-575	,	_	_	_	_
8-12	576-578	20	quantity[29]	new[29]	_	_
8-13	579-580	%	quantity[29]	new[29]	_	_
8-14	581-582	,	_	_	_	_
8-15	583-586	and	_	_	_	_
8-16	587-589	22	quantity[30]|abstract[31]	new[30]|new[31]	coref|coref	16-13[105_31]|16-13[105_31]
8-17	590-591	%	quantity[30]|abstract[31]	new[30]|new[31]	_	_
8-18	592-602	diagnostic	abstract[31]	new[31]	_	_
8-19	603-608	yield	abstract[31]	new[31]	_	_
8-20	609-610	.	_	_	_	_

#Text=In those reports , for example , frequent variants , such as p. ( Glu148Gln ) ( MEFV ) , p. ( Arg121Gln ) ( TNFRSF1A ) , or p. ( Val198Met ) ( NLRP3 ) , and all known susceptibility factors for inflammation were considered consistent with the diagnosis .
9-1	611-613	In	_	_	_	_
9-2	614-619	those	abstract[32]	giv[32]	_	_
9-3	620-627	reports	abstract[32]	giv[32]	_	_
9-4	628-629	,	_	_	_	_
9-5	630-633	for	_	_	_	_
9-6	634-641	example	_	_	_	_
9-7	642-643	,	_	_	_	_
9-8	644-652	frequent	object[33]	new[33]	coref	14-13[91_33]
9-9	653-661	variants	object[33]	new[33]	_	_
9-10	662-663	,	object[33]	new[33]	_	_
9-11	664-668	such	object[33]	new[33]	_	_
9-12	669-671	as	object[33]	new[33]	_	_
9-13	672-674	p.	object[33]|place	new[33]|new	coref	9-30
9-14	675-676	(	_	_	_	_
9-15	677-686	Glu148Gln	abstract	new	appos	9-18
9-16	687-688	)	_	_	_	_
9-17	689-690	(	_	_	_	_
9-18	691-695	MEFV	abstract	giv	coref	12-3[73_0]
9-19	696-697	)	_	_	_	_
9-20	698-699	,	_	_	_	_
9-21	700-702	p.	place	new	_	_
9-22	703-704	(	_	_	_	_
9-23	705-714	Arg121Gln	organization	new	_	_
9-24	715-716	)	_	_	_	_
9-25	717-718	(	_	_	_	_
9-26	719-727	TNFRSF1A	abstract	new	_	_
9-27	728-729	)	_	_	_	_
9-28	730-731	,	_	_	_	_
9-29	732-734	or	_	_	_	_
9-30	735-737	p.	place	giv	_	_
9-31	738-739	(	_	_	_	_
9-32	740-749	Val198Met	abstract	new	appos	9-35
9-33	750-751	)	_	_	_	_
9-34	752-753	(	_	_	_	_
9-35	754-759	NLRP3	abstract	giv	_	_
9-36	760-761	)	_	_	_	_
9-37	762-763	,	_	_	_	_
9-38	764-767	and	_	_	_	_
9-39	768-771	all	abstract[44]	new[44]	_	_
9-40	772-777	known	abstract[44]	new[44]	_	_
9-41	778-792	susceptibility	abstract|abstract[44]	new|new[44]	_	_
9-42	793-800	factors	abstract[44]	new[44]	_	_
9-43	801-804	for	abstract[44]	new[44]	_	_
9-44	805-817	inflammation	abstract[44]|abstract	new[44]|new	_	_
9-45	818-822	were	_	_	_	_
9-46	823-833	considered	_	_	_	_
9-47	834-844	consistent	_	_	_	_
9-48	845-849	with	_	_	_	_
9-49	850-853	the	abstract[46]	giv[46]	coref	10-22[52_46]
9-50	854-863	diagnosis	abstract[46]	giv[46]	_	_
9-51	864-865	.	_	_	_	_

#Text=Moreover , our definition was more stringent than these four previous studies because we considered that we could not conclude on the diagnosis when the parent ’s DNA was lacking segregation analyses of heterozygous rare VOUS .
10-1	866-874	Moreover	_	_	_	_
10-2	875-876	,	_	_	_	_
10-3	877-880	our	person|abstract[48]	giv|giv[48]	ana|ana	10-14|10-14
10-4	881-891	definition	abstract[48]	giv[48]	_	_
10-5	892-895	was	_	_	_	_
10-6	896-900	more	_	_	_	_
10-7	901-910	stringent	_	_	_	_
10-8	911-915	than	_	_	_	_
10-9	916-921	these	abstract[49]	new[49]	_	_
10-10	922-926	four	abstract[49]	new[49]	_	_
10-11	927-935	previous	abstract[49]	new[49]	_	_
10-12	936-943	studies	abstract[49]	new[49]	_	_
10-13	944-951	because	_	_	_	_
10-14	952-954	we	person	giv	ana	10-17
10-15	955-965	considered	_	_	_	_
10-16	966-970	that	_	_	_	_
10-17	971-973	we	person	giv	ana	11-13
10-18	974-979	could	_	_	_	_
10-19	980-983	not	_	_	_	_
10-20	984-992	conclude	_	_	_	_
10-21	993-995	on	_	_	_	_
10-22	996-999	the	abstract[52]	giv[52]	coref	16-15[0_52]
10-23	1000-1009	diagnosis	abstract[52]	giv[52]	_	_
10-24	1010-1014	when	_	_	_	_
10-25	1015-1018	the	abstract[54]	new[54]	_	_
10-26	1019-1025	parent	person[53]|abstract[54]	new[53]|new[54]	_	_
10-27	1026-1028	’s	person[53]|abstract[54]	new[53]|new[54]	_	_
10-28	1029-1032	DNA	abstract[54]	new[54]	_	_
10-29	1033-1036	was	_	_	_	_
10-30	1037-1044	lacking	_	_	_	_
10-31	1045-1056	segregation	abstract|abstract[56]	new|new[56]	coref|coref	30-22|30-22
10-32	1057-1065	analyses	abstract[56]	new[56]	_	_
10-33	1066-1068	of	abstract[56]	new[56]	_	_
10-34	1069-1081	heterozygous	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-35	1082-1086	rare	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-36	1087-1091	VOUS	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-37	1092-1093	.	_	_	_	_

#Text=The low performance of the AIDs panel might also be explained by our study design that did not include most of the patients with features of FMF , MKD , and DADA2 because they were screened by Sanger sequencing .
11-1	1094-1097	The	abstract[58]	new[58]	coref	19-40[120_58]
11-2	1098-1101	low	abstract[58]	new[58]	_	_
11-3	1102-1113	performance	abstract[58]	new[58]	_	_
11-4	1114-1116	of	abstract[58]	new[58]	_	_
11-5	1117-1120	the	abstract[58]|object[60]	new[58]|new[60]	_	_
11-6	1121-1125	AIDs	abstract[58]|abstract|object[60]	new[58]|giv|new[60]	coref	13-18
11-7	1126-1131	panel	abstract[58]|object[60]	new[58]|new[60]	_	_
11-8	1132-1137	might	_	_	_	_
11-9	1138-1142	also	_	_	_	_
11-10	1143-1145	be	_	_	_	_
11-11	1146-1155	explained	_	_	_	_
11-12	1156-1158	by	_	_	_	_
11-13	1159-1162	our	person|event[63]	giv|new[63]	ana|coref|ana|coref	12-23|30-5[196_63]|12-23|30-5[196_63]
11-14	1163-1168	study	object|event[63]	new|new[63]	coref	12-23[78_0]
11-15	1169-1175	design	event[63]	new[63]	_	_
11-16	1176-1180	that	_	_	_	_
11-17	1181-1184	did	_	_	_	_
11-18	1185-1188	not	_	_	_	_
11-19	1189-1196	include	_	_	_	_
11-20	1197-1201	most	person[64]	giv[64]	ana	11-34[0_64]
11-21	1202-1204	of	person[64]	giv[64]	_	_
11-22	1205-1208	the	person[64]	giv[64]	_	_
11-23	1209-1217	patients	person[64]	giv[64]	_	_
11-24	1218-1222	with	person[64]	giv[64]	_	_
11-25	1223-1231	features	person[64]|abstract[65]	giv[64]|new[65]	coref	27-11[178_65]
11-26	1232-1234	of	person[64]|abstract[65]	giv[64]|new[65]	_	_
11-27	1235-1238	FMF	person[64]|abstract[65]|abstract	giv[64]|new[65]|new	coref	14-4
11-28	1239-1240	,	person[64]|abstract[65]	giv[64]|new[65]	_	_
11-29	1241-1244	MKD	person[64]|abstract[65]|event	giv[64]|new[65]|new	_	_
11-30	1245-1246	,	person[64]|abstract[65]	giv[64]|new[65]	_	_
11-31	1247-1250	and	person[64]|abstract[65]	giv[64]|new[65]	_	_
11-32	1251-1256	DADA2	person[64]|abstract[65]|abstract	giv[64]|new[65]|new	_	_
11-33	1257-1264	because	_	_	_	_
11-34	1265-1269	they	person	giv	coref	15-4[96_0]
11-35	1270-1274	were	_	_	_	_
11-36	1275-1283	screened	_	_	_	_
11-37	1284-1286	by	_	_	_	_
11-38	1287-1293	Sanger	person|object[71]	new|new[71]	coref|coref	34-49|34-49
11-39	1294-1304	sequencing	object[71]	new[71]	_	_
11-40	1305-1306	.	_	_	_	_

#Text=Still , the genes MEFV , MVK , and ADA2 remained among the four most frequently involved in the conclusive diagnoses of our study .
12-1	1307-1312	Still	_	_	_	_
12-2	1313-1314	,	_	_	_	_
12-3	1315-1318	the	abstract[72]|abstract[73]	new[72]|giv[73]	coref|coref|coref|coref	15-19[0_73]|32-21[214_72]|15-19[0_73]|32-21[214_72]
12-4	1319-1324	genes	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
12-5	1325-1329	MEFV	abstract[73]	giv[73]	_	_
12-6	1330-1331	,	_	_	_	_
12-7	1332-1335	MVK	object	new	coref	34-16
12-8	1336-1337	,	_	_	_	_
12-9	1338-1341	and	_	_	_	_
12-10	1342-1346	ADA2	abstract	new	_	_
12-11	1347-1355	remained	_	_	_	_
12-12	1356-1361	among	_	_	_	_
12-13	1362-1365	the	_	_	_	_
12-14	1366-1370	four	_	_	_	_
12-15	1371-1375	most	_	_	_	_
12-16	1376-1386	frequently	_	_	_	_
12-17	1387-1395	involved	_	_	_	_
12-18	1396-1398	in	_	_	_	_
12-19	1399-1402	the	abstract[76]	new[76]	_	_
12-20	1403-1413	conclusive	abstract[76]	new[76]	_	_
12-21	1414-1423	diagnoses	abstract[76]	new[76]	_	_
12-22	1424-1426	of	abstract[76]	new[76]	_	_
12-23	1427-1430	our	abstract[76]|person|object[78]	new[76]|giv|giv[78]	ana|coref|ana|coref	16-2|25-3[159_78]|16-2|25-3[159_78]
12-24	1431-1436	study	abstract[76]|object[78]	new[76]|giv[78]	_	_
12-25	1437-1438	.	_	_	_	_

#Text=This observation possibly stems from a better detection by NGS of the new molecular mechanisms involved in AIDs ( mosaicism , CNVs ) and better information on these three diseases because they are among the best-described AIDs .
13-1	1439-1443	This	event[79]	new[79]	_	_
13-2	1444-1455	observation	event[79]	new[79]	_	_
13-3	1456-1464	possibly	_	_	_	_
13-4	1465-1470	stems	_	_	_	_
13-5	1471-1475	from	_	_	_	_
13-6	1476-1477	a	abstract[80]	new[80]	_	_
13-7	1478-1484	better	abstract[80]	new[80]	_	_
13-8	1485-1494	detection	abstract[80]	new[80]	_	_
13-9	1495-1497	by	abstract[80]	new[80]	_	_
13-10	1498-1501	NGS	abstract[80]|place[81]	new[80]|giv[81]	coref	20-5[0_81]
13-11	1502-1504	of	abstract[80]|place[81]	new[80]|giv[81]	_	_
13-12	1505-1508	the	abstract[80]|place[81]|abstract[82]	new[80]|giv[81]|new[82]	coref	32-24[215_82]
13-13	1509-1512	new	abstract[80]|place[81]|abstract[82]	new[80]|giv[81]|new[82]	_	_
13-14	1513-1522	molecular	abstract[80]|place[81]|abstract[82]	new[80]|giv[81]|new[82]	_	_
13-15	1523-1533	mechanisms	abstract[80]|place[81]|abstract[82]	new[80]|giv[81]|new[82]	_	_
13-16	1534-1542	involved	_	_	_	_
13-17	1543-1545	in	_	_	_	_
13-18	1546-1550	AIDs	abstract	giv	coref	13-35[89_0]
13-19	1551-1552	(	_	_	_	_
13-20	1553-1562	mosaicism	abstract	new	_	_
13-21	1563-1564	,	_	_	_	_
13-22	1565-1569	CNVs	abstract	new	_	_
13-23	1570-1571	)	_	_	_	_
13-24	1572-1575	and	_	_	_	_
13-25	1576-1582	better	abstract[86]	new[86]	_	_
13-26	1583-1594	information	abstract[86]	new[86]	_	_
13-27	1595-1597	on	abstract[86]	new[86]	_	_
13-28	1598-1603	these	abstract[86]|abstract[87]	new[86]|new[87]	ana	13-32[0_87]
13-29	1604-1609	three	abstract[86]|abstract[87]	new[86]|new[87]	_	_
13-30	1610-1618	diseases	abstract[86]|abstract[87]	new[86]|new[87]	_	_
13-31	1619-1626	because	_	_	_	_
13-32	1627-1631	they	abstract	giv	_	_
13-33	1632-1635	are	_	_	_	_
13-34	1636-1641	among	_	_	_	_
13-35	1642-1645	the	abstract[89]	giv[89]	coref	20-26[0_89]
13-36	1646-1660	best-described	abstract[89]	giv[89]	_	_
13-37	1661-1665	AIDs	abstract[89]	giv[89]	_	_
13-38	1666-1667	.	_	_	_	_

#Text=In addition , FMF is now recognized as a disease caused by gain-of-function variants with a dosage effect rather than a purely recessive condition .
14-1	1668-1670	In	_	_	_	_
14-2	1671-1679	addition	_	_	_	_
14-3	1680-1681	,	_	_	_	_
14-4	1682-1685	FMF	abstract	giv	_	_
14-5	1686-1688	is	_	_	_	_
14-6	1689-1692	now	_	_	_	_
14-7	1693-1703	recognized	_	_	_	_
14-8	1704-1706	as	_	_	_	_
14-9	1707-1708	a	_	_	_	_
14-10	1709-1716	disease	_	_	_	_
14-11	1717-1723	caused	_	_	_	_
14-12	1724-1726	by	_	_	_	_
14-13	1727-1743	gain-of-function	object[91]	giv[91]	coref	34-29[236_91]
14-14	1744-1752	variants	object[91]	giv[91]	_	_
14-15	1753-1757	with	object[91]	giv[91]	_	_
14-16	1758-1759	a	object[91]|abstract[93]	giv[91]|new[93]	_	_
14-17	1760-1766	dosage	object[91]|abstract|abstract[93]	giv[91]|new|new[93]	_	_
14-18	1767-1773	effect	object[91]|abstract[93]	giv[91]|new[93]	_	_
14-19	1774-1780	rather	object[91]	giv[91]	_	_
14-20	1781-1785	than	object[91]	giv[91]	_	_
14-21	1786-1787	a	object[91]|abstract[94]	giv[91]|new[94]	coref	15-12[98_94]
14-22	1788-1794	purely	object[91]|abstract[94]	giv[91]|new[94]	_	_
14-23	1795-1804	recessive	object[91]|abstract[94]	giv[91]|new[94]	_	_
14-24	1805-1814	condition	object[91]|abstract[94]	giv[91]|new[94]	_	_
14-25	1815-1816	.	_	_	_	_

#Text=For one-third of the patients with one heterozygous pathogenic variant in a recessive condition , the gene was MEFV .
15-1	1817-1820	For	_	_	_	_
15-2	1821-1830	one-third	quantity[95]	new[95]	_	_
15-3	1831-1833	of	quantity[95]	new[95]	_	_
15-4	1834-1837	the	quantity[95]|person[96]	new[95]|giv[96]	coref	19-20[113_96]
15-5	1838-1846	patients	quantity[95]|person[96]	new[95]|giv[96]	_	_
15-6	1847-1851	with	quantity[95]	new[95]	_	_
15-7	1852-1855	one	quantity[95]|object[97]	new[95]|new[97]	coref	16-8[103_97]
15-8	1856-1868	heterozygous	quantity[95]|object[97]	new[95]|new[97]	_	_
15-9	1869-1879	pathogenic	quantity[95]|object[97]	new[95]|new[97]	_	_
15-10	1880-1887	variant	quantity[95]|object[97]	new[95]|new[97]	_	_
15-11	1888-1890	in	quantity[95]|object[97]	new[95]|new[97]	_	_
15-12	1891-1892	a	quantity[95]|object[97]|abstract[98]	new[95]|new[97]|giv[98]	_	_
15-13	1893-1902	recessive	quantity[95]|object[97]|abstract[98]	new[95]|new[97]|giv[98]	_	_
15-14	1903-1912	condition	quantity[95]|object[97]|abstract[98]	new[95]|new[97]|giv[98]	_	_
15-15	1913-1914	,	_	_	_	_
15-16	1915-1918	the	abstract[99]	new[99]	_	_
15-17	1919-1923	gene	abstract[99]	new[99]	_	_
15-18	1924-1927	was	_	_	_	_
15-19	1928-1932	MEFV	abstract	giv	_	_
15-20	1933-1934	.	_	_	_	_

#Text=If we had included heterozygous carriers of a MEFV pathogenic variant , the genetic diagnosis yield would have improved up to 10 % (
16-1	1935-1937	If	_	_	_	_
16-2	1938-1940	we	person	giv	ana	19-24
16-3	1941-1944	had	_	_	_	_
16-4	1945-1953	included	_	_	_	_
16-5	1954-1966	heterozygous	person[102]	new[102]	_	_
16-6	1967-1975	carriers	person[102]	new[102]	_	_
16-7	1976-1978	of	person[102]	new[102]	_	_
16-8	1979-1980	a	person[102]|object[103]	new[102]|giv[103]	coref	34-22[0_103]
16-9	1981-1985	MEFV	person[102]|object[103]	new[102]|giv[103]	_	_
16-10	1986-1996	pathogenic	person[102]|object[103]	new[102]|giv[103]	_	_
16-11	1997-2004	variant	person[102]|object[103]	new[102]|giv[103]	_	_
16-12	2005-2006	,	_	_	_	_
16-13	2007-2010	the	abstract[105]	giv[105]	_	_
16-14	2011-2018	genetic	abstract[105]	giv[105]	_	_
16-15	2019-2028	diagnosis	abstract|abstract[105]	giv|giv[105]	coref	27-5[176_0]
16-16	2029-2034	yield	abstract[105]	giv[105]	_	_
16-17	2035-2040	would	_	_	_	_
16-18	2041-2045	have	_	_	_	_
16-19	2046-2054	improved	_	_	_	_
16-20	2055-2057	up	_	_	_	_
16-21	2058-2060	to	_	_	_	_
16-22	2061-2063	10	quantity[106]	new[106]	_	_
16-23	2064-2065	%	quantity[106]	new[106]	_	_
16-24	2066-2067	(	_	_	_	_

#Text=Figure 2
17-1	2068-2074	Figure	abstract[107]	new[107]	_	_
17-2	2075-2076	2	abstract[107]	new[107]	_	_

#Text=) .
18-1	2077-2078	)	_	_	_	_
18-2	2079-2080	.	_	_	_	_

#Text=In an attempt to find a cause that could explain the low rate of genetic confirmation using panels in the patients referred to us , we wondered whether validation of the request by a specialized reference center could improve this performance .
19-1	2081-2083	In	_	_	_	_
19-2	2084-2086	an	abstract[108]	new[108]	_	_
19-3	2087-2094	attempt	abstract[108]	new[108]	_	_
19-4	2095-2097	to	_	_	_	_
19-5	2098-2102	find	abstract	new	coref|none	23-4[149_0]|19-5[0_149]
19-6	2103-2104	a	abstract[109]	new[109]	_	_
19-7	2105-2110	cause	abstract[109]	new[109]	_	_
19-8	2111-2115	that	_	_	_	_
19-9	2116-2121	could	_	_	_	_
19-10	2122-2129	explain	_	_	_	_
19-11	2130-2133	the	abstract[110]	new[110]	_	_
19-12	2134-2137	low	abstract[110]	new[110]	_	_
19-13	2138-2142	rate	abstract[110]	new[110]	_	_
19-14	2143-2145	of	abstract[110]	new[110]	_	_
19-15	2146-2153	genetic	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
19-16	2154-2166	confirmation	abstract[110]|abstract[111]	new[110]|giv[111]	_	_
19-17	2167-2172	using	_	_	_	_
19-18	2173-2179	panels	person[112]	new[112]	coref	29-12[191_112]
19-19	2180-2182	in	person[112]	new[112]	_	_
19-20	2183-2186	the	person[112]|person[113]	new[112]|giv[113]	coref	20-24[128_113]
19-21	2187-2195	patients	person[112]|person[113]	new[112]|giv[113]	_	_
19-22	2196-2204	referred	_	_	_	_
19-23	2205-2207	to	_	_	_	_
19-24	2208-2210	us	person	giv	ana	19-26
19-25	2211-2212	,	_	_	_	_
19-26	2213-2215	we	person	giv	ana	22-1
19-27	2216-2224	wondered	_	_	_	_
19-28	2225-2232	whether	_	_	_	_
19-29	2233-2243	validation	abstract[116]	new[116]	_	_
19-30	2244-2246	of	abstract[116]	new[116]	_	_
19-31	2247-2250	the	abstract[116]|abstract[117]	new[116]|new[117]	_	_
19-32	2251-2258	request	abstract[116]|abstract[117]	new[116]|new[117]	_	_
19-33	2259-2261	by	abstract[116]|abstract[117]	new[116]|new[117]	_	_
19-34	2262-2263	a	abstract[116]|abstract[117]|place[119]	new[116]|new[117]|new[119]	coref	26-3[169_119]
19-35	2264-2275	specialized	abstract[116]|abstract[117]|place[119]	new[116]|new[117]|new[119]	_	_
19-36	2276-2285	reference	abstract[116]|abstract[117]|person|place[119]	new[116]|new[117]|new|new[119]	coref	21-2
19-37	2286-2292	center	abstract[116]|abstract[117]|place[119]	new[116]|new[117]|new[119]	_	_
19-38	2293-2298	could	_	_	_	_
19-39	2299-2306	improve	_	_	_	_
19-40	2307-2311	this	abstract[120]	giv[120]	_	_
19-41	2312-2323	performance	abstract[120]	giv[120]	_	_
19-42	2324-2325	.	_	_	_	_

#Text=The success of the NGS approach was suggested to rely on its use in the context of a highly specialized clinical service for patients with AIDs .
20-1	2326-2329	The	abstract[121]	new[121]	_	_
20-2	2330-2337	success	abstract[121]	new[121]	_	_
20-3	2338-2340	of	abstract[121]	new[121]	_	_
20-4	2341-2344	the	abstract[121]|abstract[123]	new[121]|giv[123]	ana	20-12[0_123]
20-5	2345-2348	NGS	abstract[121]|place|abstract[123]	new[121]|giv|giv[123]	coref	25-26
20-6	2349-2357	approach	abstract[121]|abstract[123]	new[121]|giv[123]	_	_
20-7	2358-2361	was	_	_	_	_
20-8	2362-2371	suggested	_	_	_	_
20-9	2372-2374	to	_	_	_	_
20-10	2375-2379	rely	_	_	_	_
20-11	2380-2382	on	_	_	_	_
20-12	2383-2386	its	abstract|abstract[125]	giv|new[125]	_	_
20-13	2387-2390	use	abstract[125]	new[125]	_	_
20-14	2391-2393	in	_	_	_	_
20-15	2394-2397	the	abstract[126]	new[126]	_	_
20-16	2398-2405	context	abstract[126]	new[126]	_	_
20-17	2406-2408	of	abstract[126]	new[126]	_	_
20-18	2409-2410	a	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-19	2411-2417	highly	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-20	2418-2429	specialized	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-21	2430-2438	clinical	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-22	2439-2446	service	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-23	2447-2450	for	abstract[126]|abstract[127]	new[126]|new[127]	_	_
20-24	2451-2459	patients	abstract[126]|abstract[127]|person[128]	new[126]|new[127]|giv[128]	coref	22-10[142_128]
20-25	2460-2464	with	abstract[126]|abstract[127]|person[128]	new[126]|new[127]|giv[128]	_	_
20-26	2465-2469	AIDs	abstract[126]|abstract[127]|person[128]|abstract	new[126]|new[127]|giv[128]|giv	coref	22-11
20-27	2470-2471	.	_	_	_	_

#Text=National reference centers and networks cover all the expertise necessary for patient care and operational management and efficiency .
21-1	2472-2480	National	place[131]	new[131]	coref	22-16[145_131]
21-2	2481-2490	reference	person|place[131]	giv|new[131]	coref	22-16
21-3	2491-2498	centers	place[131]	new[131]	_	_
21-4	2499-2502	and	_	_	_	_
21-5	2503-2511	networks	place	new	_	_
21-6	2512-2517	cover	_	_	_	_
21-7	2518-2521	all	abstract[133]	new[133]	_	_
21-8	2522-2525	the	abstract[133]	new[133]	_	_
21-9	2526-2535	expertise	abstract[133]	new[133]	_	_
21-10	2536-2545	necessary	abstract[133]	new[133]	_	_
21-11	2546-2549	for	_	_	_	_
21-12	2550-2557	patient	person|abstract[135]	new|new[135]	coref|coref	35-18[253_0]|35-18[253_0]
21-13	2558-2562	care	abstract[135]	new[135]	_	_
21-14	2563-2566	and	_	_	_	_
21-15	2567-2578	operational	abstract[136]	new[136]	_	_
21-16	2579-2589	management	abstract[136]	new[136]	_	_
21-17	2590-2593	and	_	_	_	_
21-18	2594-2604	efficiency	abstract	new	_	_
21-19	2605-2606	.	_	_	_	_

#Text=We established a pre-requisite for a systematic evaluation of undifferentiated AIDs patients by clinicians from reference centers .
22-1	2607-2609	We	person	giv	ana	25-3
22-2	2610-2621	established	_	_	_	_
22-3	2622-2623	a	abstract[139]	new[139]	_	_
22-4	2624-2637	pre-requisite	abstract[139]	new[139]	_	_
22-5	2638-2641	for	abstract[139]	new[139]	_	_
22-6	2642-2643	a	abstract[139]|event[140]	new[139]|new[140]	_	_
22-7	2644-2654	systematic	abstract[139]|event[140]	new[139]|new[140]	_	_
22-8	2655-2665	evaluation	abstract[139]|event[140]	new[139]|new[140]	_	_
22-9	2666-2668	of	abstract[139]|event[140]	new[139]|new[140]	_	_
22-10	2669-2685	undifferentiated	abstract[139]|event[140]|person[142]	new[139]|new[140]|giv[142]	coref	23-17[152_142]
22-11	2686-2690	AIDs	abstract[139]|event[140]|abstract|person[142]	new[139]|new[140]|giv|giv[142]	coref	28-24
22-12	2691-2699	patients	abstract[139]|event[140]|person[142]	new[139]|new[140]|giv[142]	_	_
22-13	2700-2702	by	abstract[139]|event[140]|person[142]	new[139]|new[140]|giv[142]	_	_
22-14	2703-2713	clinicians	abstract[139]|event[140]|person[142]|person[143]	new[139]|new[140]|giv[142]|new[143]	coref	33-10[222_143]
22-15	2714-2718	from	abstract[139]|event[140]|person[142]|person[143]	new[139]|new[140]|giv[142]|new[143]	_	_
22-16	2719-2728	reference	abstract[139]|event[140]|person[142]|person[143]|person|place[145]	new[139]|new[140]|giv[142]|new[143]|giv|giv[145]	coref|coref|coref|coref	23-8[148_145]|26-4|23-8[148_145]|26-4
22-17	2729-2736	centers	abstract[139]|event[140]|person[142]|person[143]|place[145]	new[139]|new[140]|giv[142]|new[143]|giv[145]	_	_
22-18	2737-2738	.	_	_	_	_

#Text=It is possible that many doctors from non-reference centers could not find the time to present their patients to MSM .
23-1	2739-2741	It	abstract	new	cata	23-1[0_149]
23-2	2742-2744	is	_	_	_	_
23-3	2745-2753	possible	_	_	_	_
23-4	2754-2758	that	abstract[149]	new[149]	_	_
23-5	2759-2763	many	person[147]|abstract[149]	new[147]|new[149]	ana	23-17[0_147]
23-6	2764-2771	doctors	person[147]|abstract[149]	new[147]|new[149]	_	_
23-7	2772-2776	from	person[147]|abstract[149]	new[147]|new[149]	_	_
23-8	2777-2790	non-reference	person[147]|place[148]|abstract[149]	new[147]|giv[148]|new[149]	coref	24-14[157_148]
23-9	2791-2798	centers	person[147]|place[148]|abstract[149]	new[147]|giv[148]|new[149]	_	_
23-10	2799-2804	could	abstract[149]	new[149]	_	_
23-11	2805-2808	not	abstract[149]	new[149]	_	_
23-12	2809-2813	find	abstract[149]	new[149]	_	_
23-13	2814-2817	the	abstract[149]|time[150]	new[149]|new[150]	coref	33-14[224_150]
23-14	2818-2822	time	abstract[149]|time[150]	new[149]|new[150]	_	_
23-15	2823-2825	to	_	_	_	_
23-16	2826-2833	present	_	_	_	_
23-17	2834-2839	their	person|person[152]	giv|giv[152]	coref|coref	24-11[0_152]|24-11[0_152]
23-18	2840-2848	patients	person[152]	giv[152]	_	_
23-19	2849-2851	to	_	_	_	_
23-20	2852-2855	MSM	abstract	new	coref	35-5[250_0]
23-21	2856-2857	.	_	_	_	_

#Text=This certainly accounts for the decrease in the proportion of patients referred by the non-reference centers .
24-1	2858-2862	This	_	_	_	_
24-2	2863-2872	certainly	_	_	_	_
24-3	2873-2881	accounts	_	_	_	_
24-4	2882-2885	for	_	_	_	_
24-5	2886-2889	the	event[154]	new[154]	_	_
24-6	2890-2898	decrease	event[154]	new[154]	_	_
24-7	2899-2901	in	event[154]	new[154]	_	_
24-8	2902-2905	the	event[154]|quantity[155]	new[154]|giv[155]	_	_
24-9	2906-2916	proportion	event[154]|quantity[155]	new[154]|giv[155]	_	_
24-10	2917-2919	of	event[154]|quantity[155]	new[154]|giv[155]	_	_
24-11	2920-2928	patients	event[154]|quantity[155]|person	new[154]|giv[155]|giv	coref	27-2[175_0]
24-12	2929-2937	referred	_	_	_	_
24-13	2938-2940	by	_	_	_	_
24-14	2941-2944	the	place[157]	giv[157]	coref	36-4[257_157]
24-15	2945-2958	non-reference	place[157]	giv[157]	_	_
24-16	2959-2966	centers	place[157]	giv[157]	_	_
24-17	2967-2968	.	_	_	_	_

#Text=However , our study showed that this strategy resulted in a better clinical filter for ordering genetic tests and almost doubled the performance of our NGS strategy .
25-1	2969-2976	However	_	_	_	_
25-2	2977-2978	,	_	_	_	_
25-3	2979-2982	our	person|object[159]	giv|giv[159]	ana|coref|ana|coref	25-25|30-6[0_159]|25-25|30-6[0_159]
25-4	2983-2988	study	object[159]	giv[159]	_	_
25-5	2989-2995	showed	_	_	_	_
25-6	2996-3000	that	_	_	_	_
25-7	3001-3005	this	abstract[160]	new[160]	coref	25-25[166_160]
25-8	3006-3014	strategy	abstract[160]	new[160]	_	_
25-9	3015-3023	resulted	abstract	new	coref	28-1[180_0]
25-10	3024-3026	in	_	_	_	_
25-11	3027-3028	a	object[161]	new[161]	_	_
25-12	3029-3035	better	object[161]	new[161]	_	_
25-13	3036-3044	clinical	object[161]	new[161]	_	_
25-14	3045-3051	filter	object[161]	new[161]	_	_
25-15	3052-3055	for	_	_	_	_
25-16	3056-3064	ordering	_	_	_	_
25-17	3065-3072	genetic	object[162]	new[162]	coref	26-21[173_162]
25-18	3073-3078	tests	object[162]	new[162]	_	_
25-19	3079-3082	and	_	_	_	_
25-20	3083-3089	almost	_	_	_	_
25-21	3090-3097	doubled	_	_	_	_
25-22	3098-3101	the	abstract[163]	new[163]	_	_
25-23	3102-3113	performance	abstract[163]	new[163]	_	_
25-24	3114-3116	of	abstract[163]	new[163]	_	_
25-25	3117-3120	our	abstract[163]|person|abstract[166]	new[163]|giv|giv[166]	ana|coref|ana|coref	26-3|35-10[251_166]|26-3|35-10[251_166]
25-26	3121-3124	NGS	abstract[163]|event|abstract[166]	new[163]|giv|giv[166]	coref	29-12
25-27	3125-3133	strategy	abstract[163]|abstract[166]	new[163]|giv[166]	_	_
25-28	3134-3135	.	_	_	_	_

#Text=Also , our reference center recently offered a diagnostic checklist to guide practitioners who may suspect an AID for ordering genetic tests .
26-1	3136-3140	Also	_	_	_	_
26-2	3141-3142	,	_	_	_	_
26-3	3143-3146	our	person|place[169]	giv|giv[169]	ana|ana	27-2|27-2
26-4	3147-3156	reference	person|place[169]	giv|giv[169]	coref	36-5
26-5	3157-3163	center	place[169]	giv[169]	_	_
26-6	3164-3172	recently	_	_	_	_
26-7	3173-3180	offered	_	_	_	_
26-8	3181-3182	a	abstract[170]	new[170]	_	_
26-9	3183-3193	diagnostic	abstract[170]	new[170]	_	_
26-10	3194-3203	checklist	abstract[170]	new[170]	_	_
26-11	3204-3206	to	_	_	_	_
26-12	3207-3212	guide	_	_	_	_
26-13	3213-3226	practitioners	person	new	_	_
26-14	3227-3230	who	_	_	_	_
26-15	3231-3234	may	_	_	_	_
26-16	3235-3242	suspect	_	_	_	_
26-17	3243-3245	an	abstract[172]	new[172]	coref	27-9[0_172]
26-18	3246-3249	AID	abstract[172]	new[172]	_	_
26-19	3250-3253	for	_	_	_	_
26-20	3254-3262	ordering	_	_	_	_
26-21	3263-3270	genetic	abstract[173]	giv[173]	_	_
26-22	3271-3276	tests	abstract[173]	giv[173]	_	_
26-23	3277-3278	.	_	_	_	_

#Text=In our patients with a conclusive diagnosis of AID , the main features identified were mucocutaneous , articular , and gastro-intestinal .
27-1	3279-3281	In	_	_	_	_
27-2	3282-3285	our	person|person[175]	giv|giv[175]	ana|coref|ana|coref	29-1|30-11[198_175]|29-1|30-11[198_175]
27-3	3286-3294	patients	person[175]	giv[175]	_	_
27-4	3295-3299	with	person[175]	giv[175]	_	_
27-5	3300-3301	a	person[175]|abstract[176]	giv[175]|giv[176]	coref	32-34[218_176]
27-6	3302-3312	conclusive	person[175]|abstract[176]	giv[175]|giv[176]	_	_
27-7	3313-3322	diagnosis	person[175]|abstract[176]	giv[175]|giv[176]	_	_
27-8	3323-3325	of	person[175]|abstract[176]	giv[175]|giv[176]	_	_
27-9	3326-3329	AID	person[175]|abstract[176]|abstract	giv[175]|giv[176]|giv	coref	36-19[259_0]
27-10	3330-3331	,	_	_	_	_
27-11	3332-3335	the	abstract[178]	giv[178]	_	_
27-12	3336-3340	main	abstract[178]	giv[178]	_	_
27-13	3341-3349	features	abstract[178]	giv[178]	_	_
27-14	3350-3360	identified	_	_	_	_
27-15	3361-3365	were	_	_	_	_
27-16	3366-3379	mucocutaneous	_	_	_	_
27-17	3380-3381	,	_	_	_	_
27-18	3382-3391	articular	_	_	_	_
27-19	3392-3393	,	_	_	_	_
27-20	3394-3397	and	_	_	_	_
27-21	3398-3415	gastro-intestinal	person	new	_	_
27-22	3416-3417	.	_	_	_	_

#Text=This result reflects daily practice because the cutaneous/mucosal , digestive tract , and musculoskeletal systems are the three most common systems involved in AIDs .
28-1	3418-3422	This	abstract[180]	new[180]	_	_
28-2	3423-3429	result	abstract[180]	new[180]	_	_
28-3	3430-3438	reflects	_	_	_	_
28-4	3439-3444	daily	abstract[181]	new[181]	_	_
28-5	3445-3453	practice	abstract[181]	new[181]	_	_
28-6	3454-3461	because	_	_	_	_
28-7	3462-3465	the	abstract[182]	new[182]	_	_
28-8	3466-3483	cutaneous/mucosal	abstract[182]	new[182]	_	_
28-9	3484-3485	,	_	_	_	_
28-10	3486-3495	digestive	object[183]	new[183]	_	_
28-11	3496-3501	tract	object[183]	new[183]	_	_
28-12	3502-3503	,	_	_	_	_
28-13	3504-3507	and	_	_	_	_
28-14	3508-3523	musculoskeletal	abstract[184]	new[184]	coref	28-17[185_184]
28-15	3524-3531	systems	abstract[184]	new[184]	_	_
28-16	3532-3535	are	_	_	_	_
28-17	3536-3539	the	abstract[185]	giv[185]	ana	30-9[197_185]
28-18	3540-3545	three	abstract[185]	giv[185]	_	_
28-19	3546-3550	most	abstract[185]	giv[185]	_	_
28-20	3551-3557	common	abstract[185]	giv[185]	_	_
28-21	3558-3565	systems	abstract[185]	giv[185]	_	_
28-22	3566-3574	involved	_	_	_	_
28-23	3575-3577	in	_	_	_	_
28-24	3578-3582	AIDs	abstract	giv	coref	29-15[192_0]
28-25	3583-3584	.	_	_	_	_

#Text=We cannot rule out a relative underestimation of the potential of NGS panels for AIDs in general .
29-1	3585-3587	We	person	giv	ana	30-5
29-2	3588-3594	cannot	_	_	_	_
29-3	3595-3599	rule	_	_	_	_
29-4	3600-3603	out	_	_	_	_
29-5	3604-3605	a	abstract[188]	new[188]	_	_
29-6	3606-3614	relative	abstract[188]	new[188]	_	_
29-7	3615-3630	underestimation	abstract[188]	new[188]	_	_
29-8	3631-3633	of	abstract[188]	new[188]	_	_
29-9	3634-3637	the	abstract[188]|abstract[189]	new[188]|new[189]	_	_
29-10	3638-3647	potential	abstract[188]|abstract[189]	new[188]|new[189]	_	_
29-11	3648-3650	of	abstract[188]|abstract[189]	new[188]|new[189]	_	_
29-12	3651-3654	NGS	abstract[188]|abstract[189]|abstract|person[191]	new[188]|new[189]|giv|giv[191]	coref|coref	30-20|30-20
29-13	3655-3661	panels	abstract[188]|abstract[189]|person[191]	new[188]|new[189]|giv[191]	_	_
29-14	3662-3665	for	abstract[188]|abstract[189]|person[191]	new[188]|new[189]|giv[191]	_	_
29-15	3666-3670	AIDs	abstract[188]|abstract[189]|person[191]|abstract[192]	new[188]|new[189]|giv[191]|giv[192]	coref	32-28[0_192]
29-16	3671-3673	in	abstract[188]|abstract[189]|person[191]|abstract[192]	new[188]|new[189]|giv[191]|giv[192]	_	_
29-17	3674-3681	general	abstract[188]|abstract[189]|person[191]|abstract[192]|person	new[188]|new[189]|giv[191]|giv[192]|new	_	_
29-18	3682-3683	.	_	_	_	_

#Text=Indeed , because of our study design , some of the patients or their relatives were not available for NGS or segregation analysis .
30-1	3684-3690	Indeed	_	_	_	_
30-2	3691-3692	,	_	_	_	_
30-3	3693-3700	because	_	_	_	_
30-4	3701-3703	of	_	_	_	_
30-5	3704-3707	our	person|abstract[196]	giv|giv[196]	ana|ana	31-3|31-3
30-6	3708-3713	study	object|abstract[196]	giv|giv[196]	_	_
30-7	3714-3720	design	abstract[196]	giv[196]	_	_
30-8	3721-3722	,	_	_	_	_
30-9	3723-3727	some	abstract[197]	giv[197]	_	_
30-10	3728-3730	of	abstract[197]	giv[197]	_	_
30-11	3731-3734	the	abstract[197]|person[198]	giv[197]|giv[198]	coref	34-32[237_198]
30-12	3735-3743	patients	abstract[197]|person[198]	giv[197]|giv[198]	_	_
30-13	3744-3746	or	abstract[197]|person[198]	giv[197]|giv[198]	_	_
30-14	3747-3752	their	abstract[197]|person[198]|person[199]	giv[197]|giv[198]|new[199]	_	_
30-15	3753-3762	relatives	abstract[197]|person[198]|person[199]	giv[197]|giv[198]|new[199]	_	_
30-16	3763-3767	were	_	_	_	_
30-17	3768-3771	not	_	_	_	_
30-18	3772-3781	available	_	_	_	_
30-19	3782-3785	for	_	_	_	_
30-20	3786-3789	NGS	abstract|abstract[202]	giv|new[202]	coref|coref	31-13|31-13
30-21	3790-3792	or	abstract[202]	new[202]	_	_
30-22	3793-3804	segregation	abstract|abstract[202]	giv|new[202]	_	_
30-23	3805-3813	analysis	abstract[202]	new[202]	_	_
30-24	3814-3815	.	_	_	_	_

#Text=However , our aim was not to evaluate the exact performance of NGS but to find ways to improve it .
31-1	3816-3823	However	_	_	_	_
31-2	3824-3825	,	_	_	_	_
31-3	3826-3829	our	person|abstract[204]	giv|new[204]	ana|ana	32-8|32-8
31-4	3830-3833	aim	abstract[204]	new[204]	_	_
31-5	3834-3837	was	_	_	_	_
31-6	3838-3841	not	_	_	_	_
31-7	3842-3844	to	_	_	_	_
31-8	3845-3853	evaluate	_	_	_	_
31-9	3854-3857	the	abstract[205]	new[205]	ana	31-20[0_205]
31-10	3858-3863	exact	abstract[205]	new[205]	_	_
31-11	3864-3875	performance	abstract[205]	new[205]	_	_
31-12	3876-3878	of	abstract[205]	new[205]	_	_
31-13	3879-3882	NGS	abstract[205]|place	new[205]|giv	coref	37-22[264_0]
31-14	3883-3886	but	_	_	_	_
31-15	3887-3889	to	_	_	_	_
31-16	3890-3894	find	_	_	_	_
31-17	3895-3899	ways	abstract	new	_	_
31-18	3900-3902	to	_	_	_	_
31-19	3903-3910	improve	_	_	_	_
31-20	3911-3913	it	abstract	giv	_	_
31-21	3914-3915	.	_	_	_	_

#Text=In addition to the successful clinical option we demonstrated here , it is easy to predict the upcoming discovery of new genes or molecular mechanisms involved in AIDs that will continue to revolutionize our routine genetic diagnosis .
32-1	3916-3918	In	_	_	_	_
32-2	3919-3927	addition	_	_	_	_
32-3	3928-3930	to	_	_	_	_
32-4	3931-3934	the	abstract[209]	new[209]	_	_
32-5	3935-3945	successful	abstract[209]	new[209]	_	_
32-6	3946-3954	clinical	abstract[209]	new[209]	_	_
32-7	3955-3961	option	abstract[209]	new[209]	_	_
32-8	3962-3964	we	person	giv	ana	32-34
32-9	3965-3977	demonstrated	_	_	_	_
32-10	3978-3982	here	_	_	_	_
32-11	3983-3984	,	_	_	_	_
32-12	3985-3987	it	abstract	new	cata	32-12[0_212]
32-13	3988-3990	is	_	_	_	_
32-14	3991-3995	easy	_	_	_	_
32-15	3996-3998	to	abstract[212]	new[212]	_	_
32-16	3999-4006	predict	abstract[212]	new[212]	_	_
32-17	4007-4010	the	abstract[212]|abstract[213]	new[212]|new[213]	_	_
32-18	4011-4019	upcoming	abstract[212]|abstract[213]	new[212]|new[213]	_	_
32-19	4020-4029	discovery	abstract[212]|abstract[213]	new[212]|new[213]	_	_
32-20	4030-4032	of	abstract[212]|abstract[213]	new[212]|new[213]	_	_
32-21	4033-4036	new	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	coref	34-69[246_214]
32-22	4037-4042	genes	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	_	_
32-23	4043-4045	or	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	_	_
32-24	4046-4055	molecular	abstract[212]|abstract[213]|abstract[214]|abstract[215]	new[212]|new[213]|giv[214]|giv[215]	_	_
32-25	4056-4066	mechanisms	abstract[212]|abstract[213]|abstract[214]|abstract[215]	new[212]|new[213]|giv[214]|giv[215]	_	_
32-26	4067-4075	involved	_	_	_	_
32-27	4076-4078	in	_	_	_	_
32-28	4079-4083	AIDs	abstract	giv	_	_
32-29	4084-4088	that	_	_	_	_
32-30	4089-4093	will	_	_	_	_
32-31	4094-4102	continue	_	_	_	_
32-32	4103-4105	to	_	_	_	_
32-33	4106-4119	revolutionize	_	_	_	_
32-34	4120-4123	our	person|abstract[218]	giv|giv[218]	_	_
32-35	4124-4131	routine	abstract[218]	giv[218]	_	_
32-36	4132-4139	genetic	abstract[218]	giv[218]	_	_
32-37	4140-4149	diagnosis	abstract[218]	giv[218]	_	_
32-38	4150-4151	.	_	_	_	_

#Text=Recent inputs of the literature advocate closer interactions between clinicians and geneticists in the era of whole-genome sequencing .
33-1	4152-4158	Recent	abstract[219]	new[219]	_	_
33-2	4159-4165	inputs	abstract[219]	new[219]	_	_
33-3	4166-4168	of	abstract[219]	new[219]	_	_
33-4	4169-4172	the	abstract[219]|abstract[220]	new[219]|new[220]	_	_
33-5	4173-4183	literature	abstract[219]|abstract[220]	new[219]|new[220]	_	_
33-6	4184-4192	advocate	_	_	_	_
33-7	4193-4199	closer	abstract[221]	new[221]	ana	34-2[0_221]
33-8	4200-4212	interactions	abstract[221]	new[221]	_	_
33-9	4213-4220	between	abstract[221]	new[221]	_	_
33-10	4221-4231	clinicians	abstract[221]|person[222]	new[221]|giv[222]	_	_
33-11	4232-4235	and	abstract[221]|person[222]	new[221]|giv[222]	_	_
33-12	4236-4247	geneticists	abstract[221]|person[222]|person[223]	new[221]|giv[222]|new[223]	coref	38-21[0_223]
33-13	4248-4250	in	abstract[221]|person[222]|person[223]	new[221]|giv[222]|new[223]	_	_
33-14	4251-4254	the	abstract[221]|person[222]|person[223]|time[224]	new[221]|giv[222]|new[223]|giv[224]	_	_
33-15	4255-4258	era	abstract[221]|person[222]|person[223]|time[224]	new[221]|giv[222]|new[223]|giv[224]	_	_
33-16	4259-4261	of	abstract[221]|person[222]|person[223]|time[224]	new[221]|giv[222]|new[223]|giv[224]	_	_
33-17	4262-4274	whole-genome	abstract[221]|person[222]|person[223]|time[224]|object[225]	new[221]|giv[222]|new[223]|giv[224]|new[225]	_	_
33-18	4275-4285	sequencing	abstract[221]|person[222]|person[223]|time[224]|object[225]	new[221]|giv[222]|new[223]|giv[224]|new[225]	_	_
33-19	4286-4287	.	_	_	_	_

#Text=Among them are the identification of genetic modifiers , affecting the penetrance of homozygous pathogenic MVK : p. ( Val377Ile ) variant ; the lack of detection of pathogenic variants in patients with a clear given phenotype , such as pathogenic canonical splice site variants not covered by Sanger and panel approaches ( e. g. , ADA2 : c. -47+2T>C ) ; or large chromosomal rearrangements , encompassing several genes in patients with complex phenotypes .
34-1	4288-4293	Among	_	_	_	_
34-2	4294-4298	them	abstract	giv	coref	34-4[227_0]
34-3	4299-4302	are	_	_	_	_
34-4	4303-4306	the	abstract[227]	giv[227]	_	_
34-5	4307-4321	identification	abstract[227]	giv[227]	_	_
34-6	4322-4324	of	abstract[227]	giv[227]	_	_
34-7	4325-4332	genetic	abstract[227]|abstract[228]	giv[227]|new[228]	_	_
34-8	4333-4342	modifiers	abstract[227]|abstract[228]	giv[227]|new[228]	_	_
34-9	4343-4344	,	_	_	_	_
34-10	4345-4354	affecting	_	_	_	_
34-11	4355-4358	the	abstract[229]	new[229]	_	_
34-12	4359-4369	penetrance	abstract[229]	new[229]	_	_
34-13	4370-4372	of	abstract[229]	new[229]	_	_
34-14	4373-4383	homozygous	abstract[229]|abstract[230]	new[229]|new[230]	_	_
34-15	4384-4394	pathogenic	abstract[229]|abstract[230]	new[229]|new[230]	_	_
34-16	4395-4398	MVK	abstract[229]|abstract	new[229]|giv	_	_
34-17	4399-4400	:	_	_	_	_
34-18	4401-4403	p.	_	_	_	_
34-19	4404-4405	(	_	_	_	_
34-20	4406-4415	Val377Ile	abstract	new	_	_
34-21	4416-4417	)	_	_	_	_
34-22	4418-4425	variant	object	giv	_	_
34-23	4426-4427	;	_	_	_	_
34-24	4428-4431	the	abstract[234]	new[234]	_	_
34-25	4432-4436	lack	abstract[234]	new[234]	_	_
34-26	4437-4439	of	abstract[234]	new[234]	_	_
34-27	4440-4449	detection	abstract[234]|abstract[235]	new[234]|new[235]	_	_
34-28	4450-4452	of	abstract[234]|abstract[235]	new[234]|new[235]	_	_
34-29	4453-4463	pathogenic	abstract[234]|abstract[235]|object[236]	new[234]|new[235]|giv[236]	_	_
34-30	4464-4472	variants	abstract[234]|abstract[235]|object[236]	new[234]|new[235]|giv[236]	_	_
34-31	4473-4475	in	abstract[234]|abstract[235]|object[236]	new[234]|new[235]|giv[236]	_	_
34-32	4476-4484	patients	abstract[234]|abstract[235]|object[236]|person[237]	new[234]|new[235]|giv[236]|giv[237]	coref	34-72[247_237]
34-33	4485-4489	with	abstract[234]|abstract[235]|object[236]|person[237]	new[234]|new[235]|giv[236]|giv[237]	_	_
34-34	4490-4491	a	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	coref	35-17[254_238]
34-35	4492-4497	clear	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-36	4498-4503	given	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-37	4504-4513	phenotype	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-38	4514-4515	,	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-39	4516-4520	such	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-40	4521-4523	as	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-41	4524-4534	pathogenic	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-42	4535-4544	canonical	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-43	4545-4551	splice	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]|organization|object[240]	new[234]|new[235]|giv[236]|giv[237]|new[238]|new|new[240]	_	_
34-44	4552-4556	site	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]|object[240]	new[234]|new[235]|giv[236]|giv[237]|new[238]|new[240]	_	_
34-45	4557-4565	variants	abstract[234]|abstract[235]|object[236]|person[237]|abstract[238]	new[234]|new[235]|giv[236]|giv[237]|new[238]	_	_
34-46	4566-4569	not	_	_	_	_
34-47	4570-4577	covered	_	_	_	_
34-48	4578-4580	by	_	_	_	_
34-49	4581-4587	Sanger	person	giv	_	_
34-50	4588-4591	and	_	_	_	_
34-51	4592-4597	panel	person|abstract[243]	new|new[243]	_	_
34-52	4598-4608	approaches	abstract[243]	new[243]	_	_
34-53	4609-4610	(	_	_	_	_
34-54	4611-4613	e.	_	_	_	_
34-55	4614-4616	g.	_	_	_	_
34-56	4617-4618	,	_	_	_	_
34-57	4619-4623	ADA2	_	_	_	_
34-58	4624-4625	:	_	_	_	_
34-59	4626-4628	c.	abstract	new	_	_
34-60	4629-4637	-47+2T>C	_	_	_	_
34-61	4638-4639	)	_	_	_	_
34-62	4640-4641	;	_	_	_	_
34-63	4642-4644	or	_	_	_	_
34-64	4645-4650	large	_	_	_	_
34-65	4651-4662	chromosomal	animal	new	_	_
34-66	4663-4677	rearrangements	_	_	_	_
34-67	4678-4679	,	_	_	_	_
34-68	4680-4692	encompassing	_	_	_	_
34-69	4693-4700	several	abstract[246]	giv[246]	_	_
34-70	4701-4706	genes	abstract[246]	giv[246]	_	_
34-71	4707-4709	in	abstract[246]	giv[246]	_	_
34-72	4710-4718	patients	abstract[246]|person[247]	giv[246]|giv[247]	_	_
34-73	4719-4723	with	abstract[246]|person[247]	giv[246]|giv[247]	_	_
34-74	4724-4731	complex	abstract[246]|person[247]|abstract[248]	giv[246]|giv[247]|new[248]	_	_
34-75	4732-4742	phenotypes	abstract[246]|person[247]|abstract[248]	giv[246]|giv[247]|new[248]	_	_
34-76	4743-4744	.	_	_	_	_

#Text=In those circumstances , an MSM could help find the best appropriate strategy in accordance with the patient ’s phenotype .
35-1	4745-4747	In	_	_	_	_
35-2	4748-4753	those	abstract[249]	new[249]	_	_
35-3	4754-4767	circumstances	abstract[249]	new[249]	_	_
35-4	4768-4769	,	_	_	_	_
35-5	4770-4772	an	abstract[250]	giv[250]	_	_
35-6	4773-4776	MSM	abstract[250]	giv[250]	_	_
35-7	4777-4782	could	_	_	_	_
35-8	4783-4787	help	_	_	_	_
35-9	4788-4792	find	_	_	_	_
35-10	4793-4796	the	abstract[251]	giv[251]	_	_
35-11	4797-4801	best	abstract[251]	giv[251]	_	_
35-12	4802-4813	appropriate	abstract[251]	giv[251]	_	_
35-13	4814-4822	strategy	abstract[251]	giv[251]	_	_
35-14	4823-4825	in	abstract[251]	giv[251]	_	_
35-15	4826-4836	accordance	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
35-16	4837-4841	with	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
35-17	4842-4845	the	abstract[251]|abstract[252]|abstract[254]	giv[251]|new[252]|giv[254]	coref	39-10[273_254]
35-18	4846-4853	patient	abstract[251]|abstract[252]|person[253]|abstract[254]	giv[251]|new[252]|giv[253]|giv[254]	_	_
35-19	4854-4856	’s	abstract[251]|abstract[252]|person[253]|abstract[254]	giv[251]|new[252]|giv[253]|giv[254]	_	_
35-20	4857-4866	phenotype	abstract[251]|abstract[252]|abstract[254]	giv[251]|new[252]|giv[254]	_	_
35-21	4867-4868	.	_	_	_	_

#Text=The role of the reference centers is to determine whether or not the clinical/anamnesis/genealogical tree is compatible with a known AID .
36-1	4869-4872	The	abstract[255]	new[255]	coref	37-11[262_255]
36-2	4873-4877	role	abstract[255]	new[255]	_	_
36-3	4878-4880	of	abstract[255]	new[255]	_	_
36-4	4881-4884	the	abstract[255]|place[257]	new[255]|giv[257]	_	_
36-5	4885-4894	reference	abstract[255]|person|place[257]	new[255]|giv|giv[257]	_	_
36-6	4895-4902	centers	abstract[255]|place[257]	new[255]|giv[257]	_	_
36-7	4903-4905	is	_	_	_	_
36-8	4906-4908	to	_	_	_	_
36-9	4909-4918	determine	_	_	_	_
36-10	4919-4926	whether	_	_	_	_
36-11	4927-4929	or	_	_	_	_
36-12	4930-4933	not	_	_	_	_
36-13	4934-4937	the	object[258]	new[258]	_	_
36-14	4938-4969	clinical/anamnesis/genealogical	object[258]	new[258]	_	_
36-15	4970-4974	tree	object[258]	new[258]	_	_
36-16	4975-4977	is	_	_	_	_
36-17	4978-4988	compatible	_	_	_	_
36-18	4989-4993	with	_	_	_	_
36-19	4994-4995	a	abstract[259]	giv[259]	_	_
36-20	4996-5001	known	abstract[259]	giv[259]	_	_
36-21	5002-5005	AID	abstract[259]	giv[259]	_	_
36-22	5006-5007	.	_	_	_	_

#Text=If compatibility does not seem to be the case , the role is to evaluate the potential added value to perform the NGS .
37-1	5008-5010	If	_	_	_	_
37-2	5011-5024	compatibility	abstract	new	_	_
37-3	5025-5029	does	_	_	_	_
37-4	5030-5033	not	_	_	_	_
37-5	5034-5038	seem	_	_	_	_
37-6	5039-5041	to	_	_	_	_
37-7	5042-5044	be	_	_	_	_
37-8	5045-5048	the	abstract[261]	new[261]	_	_
37-9	5049-5053	case	abstract[261]	new[261]	_	_
37-10	5054-5055	,	_	_	_	_
37-11	5056-5059	the	abstract[262]	giv[262]	_	_
37-12	5060-5064	role	abstract[262]	giv[262]	_	_
37-13	5065-5067	is	_	_	_	_
37-14	5068-5070	to	_	_	_	_
37-15	5071-5079	evaluate	_	_	_	_
37-16	5080-5083	the	abstract[263]	new[263]	coref	38-2[265_263]
37-17	5084-5093	potential	abstract[263]	new[263]	_	_
37-18	5094-5099	added	abstract[263]	new[263]	_	_
37-19	5100-5105	value	abstract[263]	new[263]	_	_
37-20	5106-5108	to	_	_	_	_
37-21	5109-5116	perform	_	_	_	_
37-22	5117-5120	the	place[264]	giv[264]	coref	38-14[267_264]
37-23	5121-5124	NGS	place[264]	giv[264]	_	_
37-24	5125-5126	.	_	_	_	_

#Text=If this value appears to be low , the reference center recommends that no NGS be conducted in discussion with geneticists .
38-1	5127-5129	If	_	_	_	_
38-2	5130-5134	this	abstract[265]	giv[265]	_	_
38-3	5135-5140	value	abstract[265]	giv[265]	_	_
38-4	5141-5148	appears	_	_	_	_
38-5	5149-5151	to	_	_	_	_
38-6	5152-5154	be	_	_	_	_
38-7	5155-5158	low	_	_	_	_
38-8	5159-5160	,	_	_	_	_
38-9	5161-5164	the	person[266]	new[266]	_	_
38-10	5165-5174	reference	person[266]	new[266]	_	_
38-11	5175-5181	center	person[266]	new[266]	_	_
38-12	5182-5192	recommends	_	_	_	_
38-13	5193-5197	that	_	_	_	_
38-14	5198-5200	no	place[267]	giv[267]	_	_
38-15	5201-5204	NGS	place[267]	giv[267]	_	_
38-16	5205-5207	be	_	_	_	_
38-17	5208-5217	conducted	_	_	_	_
38-18	5218-5220	in	_	_	_	_
38-19	5221-5231	discussion	abstract[268]	new[268]	coref	39-3[270_268]
38-20	5232-5236	with	abstract[268]	new[268]	_	_
38-21	5237-5248	geneticists	abstract[268]|person	new[268]|giv	_	_
38-22	5249-5250	.	_	_	_	_

#Text=Thus , this discussion decreases the number of individuals whose phenotype is not typically enough .
39-1	5251-5255	Thus	_	_	_	_
39-2	5256-5257	,	_	_	_	_
39-3	5258-5262	this	abstract[270]	giv[270]	_	_
39-4	5263-5273	discussion	abstract[270]	giv[270]	_	_
39-5	5274-5283	decreases	_	_	_	_
39-6	5284-5287	the	quantity[271]	new[271]	_	_
39-7	5288-5294	number	quantity[271]	new[271]	_	_
39-8	5295-5297	of	quantity[271]	new[271]	_	_
39-9	5298-5309	individuals	quantity[271]|person	new[271]|new	_	_
39-10	5310-5315	whose	abstract[273]	giv[273]	_	_
39-11	5316-5325	phenotype	abstract[273]	giv[273]	_	_
39-12	5326-5328	is	_	_	_	_
39-13	5329-5332	not	_	_	_	_
39-14	5333-5342	typically	_	_	_	_
39-15	5343-5349	enough	_	_	_	_
39-16	5350-5351	.	_	_	_	_
